Are we missing opportunities for early intervention in bipolar disorder? by Macneil, C.A. et al.
5ISSN 1473-7175© 2012 Expert Reviews Ltd10.1586/ERN.11.174www.expert-reviews.com
Editorial
Are we missing opportunities for early 
intervention in bipolar disorder?
Clinical staging informs the assessment, 
prognosis and choice of therapies in a 
diverse range of medical specialities, 
such as cardiac disorders and oncology. 
However, it is only relatively recently that 
psychiatry has begun to explore staging as 
a conceptual framework to understand the 
progression of psychiatric disorders, and 
how this may inform prognosis and man-
agement choices. However, a substantial 
body of new data is available to inform 
this topic. Therefore, it appears timely to 
examine some of the evidence regarding 
early intervention and the staging of clini-
cal approaches, specifically as they relate 
to bipolar disorder.
Considerable evidence has emerged in 
recent years for a staging model in medi-
cine, particularly for disorders such as 
cancer, HIV and liver disease. According 
to this model, disorders progress in identi-
fiable phases, which have specific features 
and require specifically adapted interven-
tions. There is recognition that while pro-
gression through various phases may not 
be applicable to all patients with a particu-
lar disorder, this concept can nevertheless 
reflect an aggregate picture. 
The staging model has also attracted 
interest in psychiatry as it provides the 
opportunity for specialized and stage-
appropriate interventions that may mini-
mize the risk for further illness progression, 
and facilitate recovery early in the course. 
Specifically, recent models developed for 
psychotic disorders and later adapted to 
bipolar disorders, have described categories 
ranging from stage 0 (describing and iden-
tifying risk factors for a disorder in the 
absence of any clear symptoms), through 
to stages 1a and 1b (comprising mild, non-
specific identifiable prodromal symptoms, 
respectively), stage 2 (comprising the first 
episode), stages 3a, 3b and 3c (compris-
ing subthreshold, threshold and persistent 
relapse, respectively), to stage 4 (referring to 
persisting unremitting symptoms that may 
have been nonresponsive to treatment) [1–3].
Of considerable interest in recent years, 
and as a significant cornerstone of the stag-
ing model, is the concept of neuroprogres-
sion. This concept has its roots in the work 
of Post and colleagues, who posited the con-
cept of neurosensitisation, or ‘kindling’ in 
1986 [4]. Our understanding of the neuro-
biological mechanisms that may underpin 
this phenomenon have shifted from an early 
focus on monoamines, and has become suc-
cessively broader. Specifically, cortisone, 
oxidative, mitochondrial and inflamma-
tory cytokine mechanisms are gaining 
more credibility as models of understand-
ing treatment nonresponsiveness with the 
progression of psychiatric disorders, and 
bipolar disorder in particular [5]. The shared 
mechanism of action may also go some way 
to explaining the effectiveness of medica-
tions as apparently disparate as lithium, 
valproate and antipsychotic medications, 
which have been found to increase brain-
derived neurotrophic factor in animal mod-
els [6], and share many effects on neurogen-
esis, apoptosis, inflammatory pathways and 
oxidative biology.
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“The staging model … provides the opportunity for specialized 
and stage-appropriate interventions that may minimize the risk 
for further illness progression, and facilitate recovery earlier in 
the course.”
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There are a number of reasons why a staging approach may 
be appropriate and clinically effective. Perhaps most notably, for 
some time it has been recognized that psychiatric disorders can 
present with a progressive course, with Kraepelin having observed 
that periods of wellness between relapses in bipolar disorder often 
become shorter with each episode [7]. This finding, in addition 
to evidence that bipolar disorder is characterized by progressive 
neuropathological processes, has been replicated by a significant 
volume of subsequent research [5]. 
Specifically, and of considerable clinical importance, neuro-
imaging data are emerging showing that the hippocampal volume 
loss and ventricular dilatation that occur early after the first episode 
of schizophrenia may progress with subsequent relapses in bipolar 
disorder, and that for bipolar disorder, gross brain structure is rela-
tively preserved in the early phase [8]. Consequent to this, there is 
some evidence that there are progressive neuro psychological changes 
with the course of the disorder [9]. Clearly, therefore, there is a sig-
nificant incentive to attempt to prevent the potentially deteriorating 
course of bipolar disorder through early identification and provision 
of phase-appropriate treatment. This improved rationale for early 
and appropriate intervention allows the clinician to work with the 
patient to actively prevent progression through pharmacological 
and psychological approaches.
Regarding intervention itself, the first step needs to be that of 
accurate diagnosis. It is widely recognized that bipolar disorder 
is often initially misdiagnosed, with a large study reporting that 
69% of people with bipolar disorder described being misdiagnosed 
at least once [10]. In addition, a latency period of over 12 years 
between initial onset of symptoms and commencement of treat-
ment is not uncommon [11]. However, useful reviews describing 
differentiating symptoms that may assist in early detection and 
diagnosis have been reported [11].
Research has focused on the efficacy of specific therapies at vari-
ous phases in the course of bipolar disorder. Studies by Gelenberg 
et al. [12] and Swann et al. [13] indicated that the effectiveness of 
lithium may be reduced with successive episodes. More recently, 
Berk et al. examined pooled data of 4346 participants from 
12 studies in order to establish the efficacy of an atypical anti-
psychotic in the treatment of bipolar disorder [14]. Using measures 
of mania, depression, overall global impression and relapse, it sug-
gested that individuals at the earliest stages of illness consistently 
had a more favorable response to treatment. In the Systematic 
Treatment Enhancement Program for Bipolar Disorder (STEP 
BD) database, number of episodes was robustly related to ratings 
of mania, depression, functioning and quality of life [15].
Regarding psychological treatments for bipolar disorder, 
Reinares et al. [16] and Colom [17] reported that the number of 
previous episodes had a significant effect on outcome following 
psychoeducational interventions. Similarly, Scott et al. who con-
ducted the largest trial of cognitive–behavioral therapy for bipolar 
disorder to date, found clear evidence that psychological interven-
tion was more effective in the early phase of the disorder (i.e., from 
episodes 1–6), and that cognitive–behavioral therapy actually led 
to higher relapse rates than treatment as usual for people who 
had experienced more than 30 episodes [18]. By contrast, a recent 
review by Lam et al. concluded that these interventions are effec-
tive in preventing or delaying relapse regardless of the number of 
previous episodes [19]. 
A significant aspect of early intervention in bipolar disorder is 
that it may provide a ‘window of opportunity’ to prevent, or at 
least minimize, some of the secondary morbidity that can occur 
with progressive episodes. Scott identified that, for people with 
bipolar disorder, multiple episodes could be associated with finan-
cial and employment difficulties, and self-esteem, guilt, loss and 
adjustment issues [20]. Furthermore, bipolar disorder also typically 
has its onset during late adolescence and early adulthood, which is 
widely recognized as a critical phase in an individual’s psychoso-
cial development. Therefore, interventions that focus on minimiz-
ing disruption to the developmental trajectory though utilizing 
effective psychopharmacology and implementing psychosocial 
approaches, including psychoeducation, medication adherence, 
relapse prevention, social recovery and assisting adaptation to the 
disorder, have considerable face validity. 
Functional recovery is also becoming an area of increased 
importance and interest. Much of the literature concurs that while 
approximately 90% of people achieve symptomatic recovery fol-
lowing an episode of bipolar disorder, only approxiamtely 40% 
obtain satisfactory social and occupational recovery [21,22]. This 
disparity, in addition to the importance of assisting people main-
tain social networks following a first episode of bipolar disorder, 
has been described elsewhere [23], and should clearly be a focus 
of intervention. Again, through the emerging understanding of 
the neuroprotective properties of some medications, supplements 
and psychosocial interventions, there may be an increased likeli-
hood to improve functional recovery early, which is subsequently 
associated with better trajectory of the disorder and prognosis. 
In conclusion, biological and psychological research on bipolar 
disorder provides support for a staging model in which specific 
interventions should be tailored to the phase of the disorder. This 
provides an optimistic framework for employing optimal biological 
and psychosocial interventions in the early phases of bipolar disorder 
as they could prevent the secondary consequences of the illness, and 
might be neuroprotective and prevent or minimize stage progression 
and some of the neurobiological, psychological, functional and social 
morbidity that can occur in the context of repeated episodes. This 
“A significant aspect of early intervention in 
bipolar disorder is that it may provide a ‘window of 
opportunity’ to prevent, or at least minimize, some 
of the secondary morbidity that can occur with 
progressive episodes.”
“[Staging] provides an optimistic framework for 
employing optimal biological and psychosocial 
interventions in the early phases of bipolar 
disorder.”
Macneil, Hallam, Conus, Henry, Kader & Berk
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requires early and accurate identification and diagnosis, in addi-
tion to pharmacological and psychosocial interventions designed 
to prevent both primary and secondary morbidity.
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